Overview
As life sciences companies continue to grapple with increasingly complex and continuously evolving legal, business and regulatory issues, McDermott is pleased to bring our Life Sciences Legal Leadership Forum to Chicago!
Join our cross-functional team of industry-focused life sciences lawyers for a half-day of CLE programming addressing the current state of the industry and the most pressing issues facing in-house counsel today – plus multiple networking opportunities with you in-house peers.
FEATURED SESSIONS INCLUDE:
- Navigating the FTC’s Scrutiny: Insights for In-House Counsel on Life Sciences M&A Deals and Compliance: This panel will address the Federal Trade Commission’s (FTC’s) heightened scrutiny of mergers and acquisitions (M&A) within the life sciences sector. Gain an understanding of the latest FTC enforcement trends, antitrust considerations specific to the life sciences industry, and best practices for ensuring compliance throughout the M&A process. Additionally, the panel will cover strategies for navigating post-deal integration and ongoing regulatory obligations, equipping you with key knowledge to support your clients in managing risks and seizing opportunities in this evolving landscape.
- Data Privacy and IP Considerations in AI: What In-House Legal Teams Need to Know: Delve into the transformative role of artificial intelligence (AI) in the life sciences sector, focusing on intellectual property (IP) and privacy considerations presented by AI integration in life sciences. Topics will include IP protection strategies, regulatory compliance, and data privacy and security issues. Gain valuable insights into navigating the complex legal landscape, advising your organization on leveraging AI technologies while ensuring robust IP protection, and implementing effective privacy and risk management strategies.
- FCPA Compliance in Life Sciences: Delve into the complexities of the Foreign Corrupt Practices Act (FCPA) and its implications for your operations. This panel will cover the latest enforcement trends, compliance challenges, and best practices for navigating FCPA issues in the life sciences industry. Join us to understand how you can effectively manage FCPA risks as in-house counsel and ensure adherence to global anti-corruption standards.
- Noncompetes in Life Sciences: What Now?: Noncompete clauses have long been a cornerstone strategy for maintaining competitive advantages across the life sciences industry. However, the FTC’s recent ban has precipitated a paradigm shift, forcing organizations to rapidly assess and adapt to the Final Rule’s implications. This panel will discuss how these regulatory changes are shaping the industry, address key issues such as employee mobility and compliance challenges, and update attendees on the latest federal and state developments.
